pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Facioscapulohumeral Muscular Dystrophy (FSHD)
drug
save

Facioscapulohumeral Muscular Dystrophy (FSHD)

Preclinicalupdated 6mo ago
by Altay Therapeutics Inc
Preclinical
community read0 votes

all catalysts(0)

nothing on the calendar yet

News(10)

  • Sarepta’s new CEO confident in clinical execution as DMD competitors close in
    Sarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.
    biospace · 10d ago
  • On the move: 4 rare disease companies hiring now
    Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat spinal muscular atrophy and Alexander disease.
    biospace · 1mo ago
  • Epicrispr builds case for FSHD treatment with updated data for EPI-321
    Epicrispr Biotechnologies continued to show encouraging findings from testing of its epigenetic editing treatment for the genetic muscle disease facioscapulohumeral muscular dystrophy. Twelve peopl…
    endpoints · 1mo ago
  • Roche drops muscle-sparing obesity antibody after flunked interim analysis
    Roche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.
    fiercebiotech · 1mo ago
  • After Novartis’ devastating M&A losses, long live the executive willing to try
    Big Pharma needs more—not fewer—bold bets on rare and difficult diseases after Novartis’ efforts to invest in muscular dystrophy and ALS hit major roadblocks this month.
    biospace · 2mo ago
  • Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
    The phase 3 Harbor trial of Novartis’ del-desiran has missed its primary endpoint, dealing a major blow to an asset that the Swiss drugmaker acquired in the $12 billion takeover of Avidity Bioscien…
    fiercebiotech · 2mo ago
  • Epicrispr, Infinimmune snag combined $165M in VC cash
    Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
    biospace · 3mo ago
  • Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
    The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.
    biopharma_dive · 3mo ago
  • Epicrispr raises $90M to rewrite treatment of rare muscle disease
    Epicrispr Biotechnologies has raised $90 million in a series C round backed by investors including Sanofi Ventures, positioning the biotech to advance a pipeline of epigenetic medicines led by an e…
    fiercebiotech · 3mo ago
  • 4 potential biotech M&A targets, plus a pretty sure bet from J&J
    Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
    biospace · 3mo ago
view all news mentions →
indication
Facioscapulohumeral Muscular Dystrophy (FSHD)
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?